Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR22247244

— · cohortSC

fc0759e3-7803-582b-9df0-9baa5480d9e6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSC
subtype
cohortSC

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • BILE_ACID_METABOLISM+0.580
  • XENOBIOTIC_METABOLISM+0.550
  • OXIDATIVE_PHOSPHORYLATION+0.530
  • FATTY_ACID_METABOLISM+0.520
  • PEROXISOME+0.490
  • PANCREAS_BETA_CELLS+0.480
  • CHOLESTEROL_HOMEOSTASIS+0.420
  • COAGULATION+0.420
  • ADIPOGENESIS+0.330
  • E2F_TARGETS+0.310

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
  • ALLOGRAFT_REJECTION-0.300
  • TNFA_SIGNALING_VIA_NFKB-0.300
  • MYC_TARGETS_V2-0.290
  • INFLAMMATORY_RESPONSE-0.230
  • WNT_BETA_CATENIN_SIGNALING-0.230
  • IL6_JAK_STAT3_SIGNALING-0.210
  • INTERFERON_GAMMA_RESPONSE-0.180
  • MYOGENESIS-0.180
  • ANGIOGENESIS-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
132adc071-1061-45e9-9600-256135f594d9
colon-landscapes@1
——0.845
2AUR-AD9F-TTM3-A-1-1-R-A542-39
breast-umap@18
—C0.755
3AUR-AD9I-TTM3-A-1-1-R-A542-39
breast-umap@18
—C0.748
4MBCProject_0040_T2_RNA
breast-umap@18
—C0.746
5TCGA-A8-A07P-01A-11R-A00Z-07
breast-umap@18
—B0.735
6SRR1516095
bladder-landscape@3
——0.719
7JHH5_LIVER
ccle-hcc@v2024.1
HCC—0.718
8SRR4296070
lung-landscapes@6
—cohortA10.710
9148130
medullo-epn-umap@date-based
EPNSupratentorial EPN0.702
10GSM5359435
bladder-landscape@3
——0.701

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
BILE_ACID_METABOLISM0.580Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.550Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.530Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.520Inavolisib— uncovered
PEROXISOME0.490Idelalisib— uncovered
PANCREAS_BETA_CELLS0.480Cobimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.420Remibrutinib— uncovered
COAGULATION0.420Binimetinib— uncovered
ADIPOGENESIS0.330Inavolisib— uncovered
E2F_TARGETS0.310Inavolisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
MYC_TARGETS_V10.280Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.220Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.210Idelalisib— uncovered
UV_RESPONSE_UP0.210Idelalisib— uncovered
G2M_CHECKPOINT0.180Inavolisib— uncovered
PROTEIN_SECRETION0.150Remibrutinib— uncovered
COMPLEMENT0.140Inavolisib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.140Idelalisib— uncovered